Pleurodynia Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-11　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 161.1 Mn
2033 年預估規模: USD 240.64 Mn
年複合成長率 CAGR: 5.9%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-11頁數 168報告編號 CMI9323

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Pleurodynia Treatment Market, By Treatment Modality (Pharmacological Therapies, and Non Pharmacological Therapies and Combination Therapies), By Symptoms (Chest Pain, Fever, Cough, Headache, Sore Throat, and Muscular Aches and Pains), By Patient Type (Adult, Geriatric, and Pediatric), By Healthcare Setting (Hospital, Ambulatory/Outpatient Clinics, and Home Healthcare), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Healthcare Providers, Hospitals, Clinics, and Patients/Consumers), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

According to Coherent Market Insights, the global pleurodynia treatment market is estimated to be valued at USD 161.1 Mn in 2026 and is expected to reach USD 240.6 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2026 to 2033. Pleurodynia, commonly referred to as epidemic myalgia or Bornholm disease, represents a viral infection primarily caused by Coxsackievirus B, characterized by intense chest and upper abdominal pain that mimics cardiac or pulmonary conditions. This acute febrile illness predominantly affects children and young adults, presenting with sharp, intermittent pain in the chest wall muscles and diaphragm, often accompanied by fever, headache, and malaise. The global pleurodynia treatment market encompasses pharmaceutical interventions, supportive care therapies, and diagnostic solutions aimed at managing this self-limiting yet debilitating condition. Treatment protocols typically involve symptomatic management through analgesics, anti-inflammatory medications, and antiviral agents in severe cases, while supportive measures include rest, hydration, and respiratory support when necessary. The market landscape is evolving with increased awareness of enteroviral infections, improved diagnostic capabilities, and the development of targeted therapeutic approaches. Healthcare providers face challenges in accurate diagnosis due to symptom overlap with other respiratory and cardiac conditions, driving demand for enhanced diagnostic tools and treatment protocols. The growing incidence of viral outbreaks, coupled with improved healthcare infrastructure in developing regions, continues to shape market dynamics and treatment accessibility globally. Market Dynamics The global pleurodynia treatment market experiences significant growth driven by increasing awareness about enteroviral infections among healthcare professionals and patients, leading to improved diagnosis rates and subsequent treatment demand. Rising incidence of viral outbreaks, particularly in crowded environments such as schools and military facilities, creates sustained market demand for effective therapeutic interventions. Enhanced diagnostic capabilities, including advanced molecular testing and point-of-care diagnostics, enable faster identification of causative agents, promoting timely treatment initiation and driving market expansion. Growing healthcare expenditure in emerging economies, coupled with improved access to antiviral medications and pain management therapies, contributes to market growth across diverse geographical regions. However, the market faces substantial restraints including the self-limiting nature of pleurodynia, which often resolves without specific treatment, potentially limiting pharmaceutical intervention requirements. Misdiagnosis remains a significant challenge due to symptom similarity with cardiac and pulmonary conditions, leading to inappropriate treatment protocols and market inefficiencies. Limited awareness among primary care physicians about differential diagnosis techniques may result in underreporting and suboptimal treatment approaches. Additionally, the absence of specific antiviral therapies for certain enteroviral strains constrains treatment options and market potential. Despite these challenges, opportunities emerge through development of novel antiviral compounds targeting specific enteroviral mechanisms, creating potential for breakthrough therapies. Expanding telemedicine platforms offer opportunities for remote consultation and monitoring, particularly valuable in outbreak scenarios. Investment in research and development for rapid diagnostic tools presents significant market opportunities, especially for point-of-care testing solutions that can differentiate pleurodynia from other chest pain etiologies, ultimately improving patient outcomes and market penetration. Key Features of the Study • This report provides in-depth analysis of the global pleurodynia treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global pleurodynia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include AbbVie Inc, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Ltd, Dr. Reddy’s Laboratories Ltd, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc, Novartis AG, Pfizer Inc, Sanofi S.A, and Sun Pharmaceutical Industries Ltd • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global pleurodynia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleurodynia treatment market Market Segmentation • Treatment Modality Insights (Revenue, USD Mn, 2021 - 2033) o Pharmacological Therapies  Analgesics  Non Steroidal Anti Inflammatory Drugs (NSAIDs)  Antiviral Agents  Muscle Relaxants  Corticosteroids o Non Pharmacological Therapies  Physical Therapy  Pain Management Procedures  Supportive Care (Rest, Hydration) o Combination Therapies  Pharmacological + Non Pharmacological • Symptoms Insights (Revenue, USD Mn, 2021 - 2033) o Chest Pain o Fever o Cough o Headache o Sore Throat o Muscular Aches and Pains • Patient Type Insights (Revenue, USD Mn, 2021 - 2033) o Adult o Geriatric o Pediatric • Healthcare Setting Insights (Revenue, USD Mn, 2021 - 2033) o Hospital o Ambulatory/Outpatient Clinics o Home Healthcare • Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • End User Insights (Revenue, USD Mn, 2021 - 2033) o Healthcare Providers o Hospitals o Clinics o Patients/Consumers • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o AbbVie Inc o AstraZeneca PLC o Bayer AG o Boehringer Ingelheim International GmbH o Bristol Myers Squibb Company o Cipla Ltd o Reddy’s Laboratories Ltd o Hoffmann La Roche Ltd o GlaxoSmithKline plc o Johnson & Johnson o Merck & Co., Inc o Novartis AG o Pfizer Inc o Sanofi S.A o Sun Pharmaceutical Industries Ltd

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Pleurodynia Treatment Market, By Treatment Modality  Global Pleurodynia Treatment Market, By Symptoms  Global Pleurodynia Treatment Market, By Patient Type  Global Pleurodynia Treatment Market, By Healthcare Setting  Global Pleurodynia Treatment Market, By Distribution Channel  Global Pleurodynia Treatment Market, By End User  Global Pleurodynia Treatment Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Pleurodynia Treatment Market, By Treatment Modality, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Pharmacological Therapies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Analgesics o Non Steroidal Anti Inflammatory Drugs (NSAIDs) o Antiviral Agents o Muscle Relaxants o Corticosteroids o Non Pharmacological Therapies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Physical Therapy o Pain Management Procedures o Supportive Care (Rest, Hydration) o Combination Therapies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Pharmacological + Non Pharmacological 5. Global Pleurodynia Treatment Market, By Symptoms, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Chest Pain  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Fever  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Cough  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Headache  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Sore Throat  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Muscular Aches and Pains  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Pleurodynia Treatment Market, By Patient Type, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Adult  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Geriatric  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Pediatric  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Pleurodynia Treatment Market, By Healthcare Setting, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Ambulatory/Outpatient Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Home Healthcare  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 8. Global Pleurodynia Treatment Market, By Distribution Channel, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 9. Global Pleurodynia Treatment Market, By End User, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Healthcare Providers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Patients/Consumers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 10. Global Pleurodynia Treatment Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 11. Competitive Landscape o AbbVie Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca PLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bayer AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Boehringer Ingelheim International GmbH  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bristol Myers Squibb Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Cipla Ltd  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Reddy’s Laboratories Ltd  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Hoffmann La Roche Ltd  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GlaxoSmithKline plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co., Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sanofi S.A  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sun Pharmaceutical Industries Ltd  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 12. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 13. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'Pleurodynia Treatment Market' - Global forecast to 2033

提及公司

AbbVie IncAstraZeneca PLCBayer AGBoehringer Ingelheim International GmbHBristol Myers Squibb CompanyCipla LtdReddy’s Laboratories LtdHoffmann La Roche LtdGlaxoSmithKline plcJohnson & JohnsonMerck & Co., IncNovartis AGPfizer IncSanofi S.ASun Pharmaceutical Industries Ltd

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們